Azita  Saleki-Gerhardt net worth and biography

Azita Saleki-Gerhardt Biography and Net Worth

EVP of AbbVie
Dr. Azita Saleki-Gerhardt is Executive Vice President, Operations, leading a global team of scientific, manufacturing, engineering, quality, and supply chain professionals responsible for supply and distribution of all AbbVie products, as well as several enterprise services, including facilities, purchasing and security.

Dr. Saleki-Gerhardt joined Abbott in 1993 as a research scientist. She has worked in key leadership positions of increasing responsibility across a broad range of areas, including science and technology and quality assurance. In 2011, she assumed the role of President, Global Pharmaceutical Operations at Abbott.  Following AbbVie’s separation from Abbott in 2013, Dr. Saleki-Gerhardt was appointed to lead Operations at AbbVie.  She also serves as the chair of AbbVie’s executive crisis management team, where she is responsible for the company’s cross-functional preparedness and response to ongoing issues.

She has been published in a number of scientific publications and has been awarded several patents related to pharmaceutical sciences.

Dr. Saleki-Gerhardt is a member of the board of directors for Entegris. She is a member of the Dean’s Advisory Boards for the School of International Studies and School of Pharmacy at the University of Wisconsin at Madison. At AbbVie, she is the executive chair of the Women Leaders in Action employee resource group. She is a recent alumna of the board of directors for United Way of Lake County.

Dr. Saleki-Gerhardt earned her bachelor’s, master’s, and doctorate degrees in pharmaceutics from the University of Wisconsin at Madison.

What is Azita Saleki-Gerhardt's net worth?

The estimated net worth of Azita Saleki-Gerhardt is at least $42.83 million as of February 21st, 2024. Dr. Saleki-Gerhardt owns 243,944 shares of AbbVie stock worth more than $42,831,688 as of December 21st. This net worth estimate does not reflect any other investments that Dr. Saleki-Gerhardt may own. Additionally, Dr. Saleki-Gerhardt receives a salary of $3,510,000.00 as EVP at AbbVie. Learn More about Azita Saleki-Gerhardt's net worth.

How old is Azita Saleki-Gerhardt?

Dr. Saleki-Gerhardt is currently 61 years old. There are 7 older executives and no younger executives at AbbVie. The oldest executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who is 70 years old. Learn More on Azita Saleki-Gerhardt's age.

What is Azita Saleki-Gerhardt's salary?

As the EVP of AbbVie Inc., Dr. Saleki-Gerhardt earns $3,510,000.00 per year. There are 3 executives that earn more than Dr. Saleki-Gerhardt. The highest earning executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who commands a salary of $7,190,000.00 per year. Learn More on Azita Saleki-Gerhardt's salary.

How do I contact Azita Saleki-Gerhardt?

The corporate mailing address for Dr. Saleki-Gerhardt and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Azita Saleki-Gerhardt's contact information.

Has Azita Saleki-Gerhardt been buying or selling shares of AbbVie?

Azita Saleki-Gerhardt has not been actively trading shares of AbbVie in the last ninety days. Most recently, Azita Saleki-Gerhardt sold 52,870 shares of the business's stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $173.71, for a transaction totalling $9,184,047.70. Following the completion of the sale, the executive vice president now directly owns 243,944 shares of the company's stock, valued at $42,375,512.24. Learn More on Azita Saleki-Gerhardt's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 13 times. They sold a total of 737,381 shares worth more than $130,442,034.24. The most recent insider tranaction occured on December, 16th when SVP Kevin K Buckbee sold 1,800 shares worth more than $310,032.00. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 12/16/2024.

Azita Saleki-Gerhardt Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/21/2024Sell52,870$173.71$9,184,047.70243,944View SEC Filing Icon  
2/17/2023Sell25,000$149.53$3,738,250.00233,208View SEC Filing Icon  
3/5/2019Sell15,797$79.03$1,248,436.9193,312View SEC Filing Icon  
9/11/2017Sell8,300$85.02$705,666.0093,099View SEC Filing Icon  
3/3/2014Sell2,443$50.25$122,760.7585,828View SEC Filing Icon  
9/17/2013Sell10,473$45.84$480,082.3266,703View SEC Filing Icon  
8/19/2013Sell1,270$43.01$54,622.7064,279View SEC Filing Icon  
8/12/2013Sell8,851$44.91$397,498.4164,237View SEC Filing Icon  
See Full Table

Azita Saleki-Gerhardt Buying and Selling Activity at AbbVie

This chart shows Azita Saleki-Gerhardt's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $175.58
Low: $170.66
High: $176.80

50 Day Range

MA: $182.56
Low: $164.91
High: $203.87

2 Week Range

Now: $175.58
Low: $151.29
High: $207.32

Volume

17,695,750 shs

Average Volume

5,604,020 shs

Market Capitalization

$310.27 billion

P/E Ratio

60.97

Dividend Yield

3.54%

Beta

0.58